Axsome therapeutics showcases innovation in sleep medicine with multiple presentations for axs-12 and solriamfetol at sleep 2025

New york, june 11, 2025 (globe newswire) -- axsome therapeutics, inc. (nasdaq: axsm), a biopharmaceutical company leading a new era in the treatment of central nervous system (cns) disorders, today announced seven presentations, including two featured oral plenary sessions, on axs-12 and solriamfetol, at sleep 2025, the 39th annual meeting of the associated professional sleep societies (apss), being held june 8-11, 2025, in seattle, washington.
AXS Ratings Summary
AXS Quant Ranking